{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:38:36Z","timestamp":1762673916724},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1007\/s40261-013-0062-4","type":"journal-article","created":{"date-parts":[[2013,2,28]],"date-time":"2013-02-28T16:30:30Z","timestamp":1362069030000},"page":"193-198","source":"Crossref","is-referenced-by-count":5,"title":["Improved Efficacy of Intramuscular Weekly Administration of Clodronate 200\u00a0mg (100\u00a0mg Twice Weekly) Compared with 100\u00a0mg (Once Weekly) for Increasing Bone Mineral Density in Postmenopausal Osteoporosis"],"prefix":"10.1007","volume":"33","author":[{"given":"Bruno","family":"Frediani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Bertoldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Pierguidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Nicosia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Picerno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Filippou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Cantarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Galeazzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,3,1]]},"reference":[{"issue":"12 Suppl","key":"62_CR1","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","volume":"88","author":"MJ Rogers","year":"2000","unstructured":"Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000;88(12 Suppl):2961\u201378.","journal-title":"Cancer"},{"issue":"5","key":"62_CR2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/jbmr.5650020506","volume":"2","author":"S Adami","year":"1987","unstructured":"Adami S, Bolzicco GP, Rizzo A, et al. The use of dichloromethylene bisphosphonate and aminobutane bisphosphonate in hypercalcemia of malignancy. Bone Miner. 1987;2(5):395\u2013404.","journal-title":"Bone Miner"},{"issue":"6","key":"62_CR3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0221-8747(84)90012-2","volume":"5","author":"S Adami","year":"1984","unstructured":"Adami S, Guarrera G, Salvagno G, et al. Sequential treatment of Paget\u2019s disease with human calcitonin and dichloromethylene diphosphonate (Cl2MDP). Metab Bone Dis Relat Res. 1984;5(6):265\u20137.","journal-title":"Metab Bone Dis Relat Res"},{"issue":"6","key":"62_CR4","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/S0022-5347(17)47663-4","volume":"134","author":"S Adami","year":"1985","unstructured":"Adami S, Salvagno G, Guarrera G, et al. Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J Urol. 1985;134(6):1152\u20134.","journal-title":"J Urol"},{"issue":"4","key":"62_CR5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0305-7372(96)90020-1","volume":"22","author":"JJ Body","year":"1996","unstructured":"Body JJ, Coleman RE, Piccart M. Use of bisphosphonates in cancer patients. Cancer Treat Rev. 1996;22(4):265\u201387.","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"62_CR6","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S8756-3282(96)00285-2","volume":"19","author":"JA Kanis","year":"1996","unstructured":"Kanis JA, Powles T, Paterson AH, et al. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone. 1996;19(6):663\u20137.","journal-title":"Bone"},{"issue":"Suppl 2","key":"62_CR7","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1007\/BF01623223","volume":"3","author":"JA Kanis","year":"1993","unstructured":"Kanis JA, McCloskey EV, Sirtori P, et al. Rationale for the use of clodronate in osteoporosis. Osteoporos Int. 1993;3(Suppl 2):S23\u20138.","journal-title":"Osteoporos Int"},{"issue":"Suppl 1","key":"62_CR8","first-page":"S63","volume":"8","author":"P Minaire","year":"1987","unstructured":"Minaire P, Depassio J, Berard E, et al. Effects of clodronate on immobilization bone loss. Bone. 1987;8(Suppl 1):S63\u20138.","journal-title":"Bone"},{"issue":"2","key":"62_CR9","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s002239900315","volume":"61","author":"TS Kaastad","year":"1997","unstructured":"Kaastad TS, Reikeras O, Madsen JE, et al. Effects of clodronate on cortical and trabecular bone in ovariectomized rats on a low calcium diet. Calcif Tissue Int. 1997;61(2):158\u201364.","journal-title":"Calcif Tissue Int"},{"issue":"2","key":"62_CR10","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/8756-3282(95)00439-4","volume":"18","author":"VT Lepola","year":"1996","unstructured":"Lepola VT, Hannuniemi R, Kippo K, et al. Long-term effects of clodronate on growing rat bone. Bone. 1996;18(2):191\u20136.","journal-title":"Bone"},{"issue":"8827","key":"62_CR11","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","volume":"340","author":"R Lahtinen","year":"1992","unstructured":"Lahtinen R, Laakso M, Palva I, et al. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group. Lancet. 1992;340(8827):1049\u201352.","journal-title":"Lancet"},{"issue":"4","key":"62_CR12","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1365-2141.2001.02851.x","volume":"113","author":"EV McCloskey","year":"2001","unstructured":"McCloskey EV, Dunn JA, Kanis JA, et al. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol. 2001;113(4):1035\u201343.","journal-title":"Br J Haematol"},{"issue":"1","key":"62_CR13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","volume":"11","author":"AH Paterson","year":"1993","unstructured":"Paterson AH, Powles TJ, Kanis JA, et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 1993;11(1):59\u201365.","journal-title":"J Clin Oncol"},{"issue":"2","key":"62_CR14","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1191\/026921601671919596","volume":"15","author":"IS Johnson","year":"2001","unstructured":"Johnson IS. Use of bisphosphonates for the treatment of metastatic bone pain. A survey of palliative physicians in the UK. Palliat Med. 2001;15(2):141\u20137.","journal-title":"Palliat Med"},{"issue":"6","key":"62_CR15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1191\/026921600701536372","volume":"14","author":"K Mannix","year":"2000","unstructured":"Mannix K, Ahmedzai SH, Anderson H, et al. Using bisphosphonates to control the pain of bone metastases: evidence-based guidelines for palliative care. Palliat Med. 2000;14(6):455\u201361.","journal-title":"Palliat Med"},{"issue":"2","key":"62_CR16","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/8756-3282(95)00442-4","volume":"18","author":"P Filipponi","year":"1996","unstructured":"Filipponi P, Cristallini S, Rizzello E, et al. Cyclical intravenous clodronate in postmenopausal osteoporosis: results of a long-term clinical trial. Bone. 1996;18(2):179\u201384.","journal-title":"Bone"},{"issue":"5","key":"62_CR17","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/jbmr.5650100505","volume":"10","author":"P Filipponi","year":"1995","unstructured":"Filipponi P, Pedetti M, Fedeli L, et al. Cyclical clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy. J Bone Miner Res. 1995;10(5):697\u2013703.","journal-title":"J Bone Miner Res"},{"key":"62_CR18","doi-asserted-by":"crossref","unstructured":"Giannini S, D\u2019Angelo A, Malvasi L, et al. Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss. Bone. 1993;14(2):137\u201341.","DOI":"10.1016\/8756-3282(93)90240-B"},{"issue":"3","key":"62_CR19","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0029-7844(96)00171-8","volume":"88","author":"S Giannini","year":"1996","unstructured":"Giannini S, D\u2019Angelo A, Sartori L, et al. Continuous and cyclical clodronate therapies and bone density in postmenopausal bone loss. Obstet Gynecol. 1996;88(3):431\u20136.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"62_CR20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1359\/jbmr.1997.12.1.103","volume":"12","author":"JE Heikkinen","year":"1997","unstructured":"Heikkinen JE, Selander KS, Laitinen K, et al. Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss. J Bone Miner Res. 1997;12(1):103\u201310.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"62_CR21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S8756-3282(98)00154-9","volume":"24","author":"M Rossini","year":"1999","unstructured":"Rossini M, Braga V, Gatti D, et al. Intramuscular clodronate therapy in postmenopausal osteoporosis. Bone. 1999;24(2):125\u20139.","journal-title":"Bone"},{"issue":"5","key":"62_CR22","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S8756-3282(98)00051-9","volume":"22","author":"J Herrala","year":"1998","unstructured":"Herrala J, Puolijoki H, Liippo K, et al. Clodronate is effective in preventing corticosteroid-induced bone loss among asthmatic patients. Bone. 1998;22(5):577\u201382.","journal-title":"Bone"},{"issue":"3","key":"62_CR23","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/01.TP.0000044363.31492.E5","volume":"75","author":"G Ippoliti","year":"2003","unstructured":"Ippoliti G, Pellegrini C, Campana C, et al. Clodronate treatment of established bone loss in cardiac recipients: a randomized study. Transplantation. 2003;75(3):330\u20134.","journal-title":"Transplantation"},{"issue":"6","key":"62_CR24","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1080\/17453670610013213","volume":"77","author":"M Hilding","year":"2006","unstructured":"Hilding M, Aspenberg P. Postoperative clodronate decreases prosthetic migration: 4-year follow-up of a randomized radiostereometric study of 50 total knee patients. Acta orthopaedica. 2006;77(6):912\u20136.","journal-title":"Acta orthopaedica"},{"issue":"2","key":"62_CR25","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/S0002-9343(99)80134-X","volume":"99","author":"CH Chesnut 3rd","year":"1995","unstructured":"Chesnut CH 3rd, McClung MR, Ensrud KE, et al. Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med. 1995;99(2):144\u201352.","journal-title":"Am J Med"},{"issue":"8","key":"62_CR26","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1359\/JBMR.050313","volume":"20","author":"PD Miller","year":"2005","unstructured":"Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res. 2005;20(8):1315\u201322.","journal-title":"J Bone Miner Res"},{"issue":"5","key":"62_CR27","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.2005.044958","volume":"65","author":"JY Reginster","year":"2006","unstructured":"Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2\u00a0year results from the MOBILE study. Ann Rheum Dis. 2006;65(5):654\u201361.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"62_CR28","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1359\/jbmr.040116","volume":"19","author":"E McCloskey","year":"2004","unstructured":"McCloskey E, Selby P, Davies M, et al. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. J Bone Miner Res. 2004;19(5):728\u201336.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"62_CR29","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1359\/jbmr.061008","volume":"22","author":"EV McCloskey","year":"2007","unstructured":"McCloskey EV, Beneton M, Charlesworth D, et al. Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res. 2007;22(1):135\u201341.","journal-title":"J Bone Miner Res"},{"key":"62_CR30","doi-asserted-by":"crossref","unstructured":"Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280(24):2077\u201382.","DOI":"10.1001\/jama.280.24.2077"},{"issue":"7","key":"62_CR31","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282(7):637\u201345.","journal-title":"JAMA"},{"issue":"1","key":"62_CR32","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11(1):83\u201391.","journal-title":"Osteoporos Int"},{"issue":"4","key":"62_CR33","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S8756-3282(03)00208-4","volume":"33","author":"B Frediani","year":"2003","unstructured":"Frediani B, Falsetti P, Baldi F, et al. Effects of 4-year treatment with once-weekly clodronate on prevention of corticosteroid-induced bone loss and fractures in patients with arthritis: evaluation with dual-energy X-ray absorptiometry and quantitative ultrasound. Bone. 2003;33(4):575\u201381.","journal-title":"Bone"},{"issue":"2","key":"62_CR34","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S8756-3282(00)00321-5","volume":"27","author":"K Laitinen","year":"2000","unstructured":"Laitinen K, Patronen A, Harju P, et al. Timing of food intake has a marked effect on the bioavailability of clodronate. Bone. 2000;27(2):293\u20136.","journal-title":"Bone"},{"issue":"3","key":"62_CR35","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S8756-3282(02)00841-4","volume":"31","author":"K Villikka","year":"2002","unstructured":"Villikka K, Perttunen K, Rosnell J, et al. The absolute bioavailability of clodronate from two different oral doses. Bone. 2002;31(3):418\u201321.","journal-title":"Bone"},{"issue":"6","key":"62_CR36","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/ageing\/afi160","volume":"34","author":"LJ Dominguez","year":"2005","unstructured":"Dominguez LJ, Galioto A, Ferlisi A, et al. Intermittent intramuscular clodronate therapy: a valuable option for older osteoporotic women. Age Ageing. 2005;34(6):633\u20136.","journal-title":"Age Ageing"},{"issue":"1","key":"62_CR37","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/11539990-000000000-00000","volume":"31","author":"B Frediani","year":"2011","unstructured":"Frediani B. Effects of two administration schemes of intramuscular clodronic acid on bone mineral density: a randomized, open-label, parallel-group study. Clin Drug Investig. 2011;31(1):43\u201350.","journal-title":"Clin Drug Investig"},{"key":"62_CR38","doi-asserted-by":"crossref","unstructured":"Genant HK, Li J, Wu CY, Shepherd JA. Vertebral fractures in osteoporosis: a new method for clinical assessment. J Clin Densitom 2000 Fall;3(3):281\u201390.","DOI":"10.1385\/JCD:3:3:281"},{"issue":"1","key":"62_CR39","first-page":"1","volume":"12","author":"T Schnitzer","year":"2000","unstructured":"Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70\u00a0mg once-weekly and alendronate 10\u00a0mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano). 2000;12(1):1\u201312.","journal-title":"Aging (Milano)"},{"issue":"18","key":"62_CR40","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809\u201322.","journal-title":"N Engl J Med"},{"issue":"5","key":"62_CR41","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00223-008-9179-5","volume":"83","author":"S Adami","year":"2008","unstructured":"Adami S, Gatti D, Bertoldo F, et al. Intramuscular neridronate in postmenopausal women with low bone mineral density. Calcif Tissue Int. 2008;83(5):301\u20137.","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"62_CR42","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0002-9343(93)90350-X","volume":"95","author":"ST Harris","year":"1993","unstructured":"Harris ST, Watts NB, Jackson RD, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med. 1993;95(6):557\u201367.","journal-title":"Am J Med"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-013-0062-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-013-0062-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-013-0062-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T16:16:35Z","timestamp":1715012195000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-013-0062-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["62"],"URL":"https:\/\/doi.org\/10.1007\/s40261-013-0062-4","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}